Regulation FD Disclosure (Form 8-K)

Item 7.01. Regulation FD Disclosure.

Pursuant to Regulation FD promulgated under the Securities Exchange Act of 1934, as amended, - OSR Holdings, Inc. (NASDAQ: OSRH) ("OSR Holdings" or the "Company") is hereby making publicly available certain information regarding the business development activities of its drug development subsidiary, Vaximm AG ("Vaximm"), that was inadvertently referenced during a meeting with a sell-side research analyst on March 13, 2026.

Background

On the morning of March 13, 2026, members of OSR Holdings' management conducted an introductory investor relations call with a healthcare analyst at a New York-based investment bank. During this call, while the Chief Executive Officer of OSR Holdings was presenting on the business development activities of Vaximm as part of the Company's broader strategic overview, certain information regarding Vaximm and SillaJen, Inc. ("SillaJen"), a publicly-listed biopharmaceutical company in South Korea (KOSDAQ: 215600), was inadvertently referenced before being made publicly available. The Company is furnishing this Item 7.01 disclosure in accordance with Regulation FD to ensure that such information is broadly available to all investors, potential investors, and the public.

Pexa-Vec Licensing Discussion

Vaximm is currently in active negotiations with SillaJen regarding a potential licensing arrangement involving Pexa-Vec, a clinical-stage oncolytic immunotherapy being developed by SillaJen for the treatment of Renal Cell Carcinoma ("RCC") and currently in a Phase 2 clinical study under the U.S. Food and Drug Administration ("FDA") regulatory framework. While these negotiations are ongoing, no binding term sheet, letter of intent, or definitive agreement has been executed with respect to any such licensing arrangement. There can be no assurance that these negotiations will result in a definitive agreement or that any licensing transaction will be consummated on the terms currently being discussed, or at all.

Preliminary Discussions Regarding SillaJen Controlling Stake

Separately, OSR Holdings wishes to disclose that its management has had preliminary and exploratory verbal discussions with the management of SillaJen regarding a potential acquisition by OSR Holdings of a controlling interest in SillaJen, representing approximately 16% of SillaJen's total outstanding shares of common stock. These discussions are at a very early and exploratory stage. No specific deal structure, transaction terms, financing arrangements, or binding documentation of any kind has been agreed upon or executed in connection with any such potential acquisition. There can be no assurance that these preliminary discussions will lead to any definitive agreement or that any transaction will be consummated.